Programme

07:00 - 20:00

REGISTRATION

08:00 - 10:00

ESPE Obesity Working Group (OWG)

test

E2

Chair: Tetyana Chaychenko (Kharkiv, Ukraine)

08:00
E2
Session starts at 08:00

WG2.1

Pathogenesis of Insulin Resistance

Ram Weiss (Jerusalem, Israel)

08:24
E2
Session starts at 08:00

WG2.2

EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project)

Tetyana Chaychenko (Kharkiv, Ukraine)

08:48
E2
Session starts at 08:00

WG2.3

Insulin function in obese children within the low and high ranges of impaired fasting glycemia

Claude Marcus (Solna, Sweden)

09:12
E2
Session starts at 08:00

WG2.4

Adolescent type 2 diabetes: Comparing prospective registries

Reinhard Holl (Ulm, Germany)

09:36
E2
Session starts at 08:00

WG2.5

Youth onset T2D (2018 ISPAD Consensus Guidelines)

Thomas Reinehr (Datteln, Germany)

08:00 - 10:00

ESPE Working Group on Disorders of Sex Development (DSD)

E1

Christa Flück (Bern, Switzerland)

08:00
E1
Session starts at 08:00

Introduction

Christa Flück (Bern, Switzerland)

08:05
E1
Session starts at 08:00

WG1.1

Epigenetics and the androgen insensitivity syndrome

Nadine Hornig (Kiel, Germany)

08:25
E1
Session starts at 08:00

WG1.2

Oligogenic origin of DSD

Nuria Camats (Barcelona, Spain)

08:45
E1
Session starts at 08:00

WG1.3

Postpubertal outcome of boys born with hypospadias

Lloyd Tack (Ghent, Belgium)

09:05
E1
Session starts at 08:00

WG1.4

Shared or Shaped Decision-Making in DSD

Jürg Streuli (Zürich, Switzerland)

09:25
E1
Session starts at 08:00

WG1.5

i-dsd/i-cah

Jillian Bryce & Faisal Ahmed (Glasgow, United Kingdom & Glasgow, United Kingdom)

09:35
E1
Session starts at 08:00

WG1.6

Endo-ERN

Anna Nordenström & Olaf Hiort (Stockholm, Sweden & Lübeck, Germany)

09:45
E1
Session starts at 08:00

Discussion with attendees

DSD panel member discussion

09:55
E1
Session starts at 08:00

Conclusion

Tülay Güran (Turkey, Istanbul)

08:00 - 10:00

ESPE Working Group on Bone and Growth Plate (BGP)

F1

Ciara McDonnell (Dublin, Ireland)

08:00
F1
Session starts at 08:00

WG3.1

Lethal pyridoxin-independent encephalopathy in a case of perinatal hypophosphatasia

Adalbert Raiman (Austria)

08:15
F1
Session starts at 08:00

WG3.2

Congenital talipes equinovarus and bowing of femur due to homozygous TRPV6 mutation

Saygin Abali (Turkey)

08:30
F1
Session starts at 08:00

WG3.3

Mechanisms of vascular calcification and potential treatment implications

Frank Rutsch (Münster, Germany)

09:05
F1
Session starts at 08:00

WG3.4

Update on BOND

Klaus Mohnike (Magdeburg, Germany)

09:25
F1
Session starts at 08:00

WG3.5

New insights in growth plate fusion

Katherine Staines (Edinburgh, Scotland)

08:00 - 10:00

ESPE Working Group on Diabetes Technology (DT)

F2

Moshe Philip (Petah Tikva, Israel)

F2
Session starts at 08:00

Introduction

Moshe Phillip (Petah Tikva, Israel)

08:05
F2
Session starts at 08:00

WG4.1

Impact of hypoglycemia on cognitive function

Jacques Beltrand (Paris, France)

08:25
F2
Session starts at 08:00

WG4.2

Impact of hyperglycemia on cognitive function

Jasna Šuput Omladič (Ljubljana, Slovenia)

08:45
F2
Session starts at 08:00

WG4.3

Type 2 diabetes and the brain

Urakami Tatsuhiko (Tokyo, Japan)

09:05
F2
Session starts at 08:00

WG4.4

Fear of hyperglycemia

Michal Nevo (Petah Tikva, Israel)

09:20
F2
Session starts at 08:00

WG4.5

Time in Range (TIR) - Highlights from the consensus meeting February 2019

Tadej Battelino (Ljubljana, Slovenia)

09:40
F2
Session starts at 08:00

WG4.6

How technology helps to improve TIR (open and closed loop)

Boris Kovatchev (Virginia, USA)

08:00 - 10:00

ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)

HALL B

Anne-Simone Parent (Liège, Belgium) & Ken Ong (Cambridge, United Kingdom)

08:00
HALL B
Session starts at 08:00

WG5.1

Early Origins of PCOS

Francis de Zegher (Leuven, Belgium)

08:23
HALL B
Session starts at 08:00

WG5.2

Diagnosis & pharmacological intervention in PCOS

Lourdes Ibáñez (Barcelona, Spain)

08:46
HALL B
Session starts at 08:00

WG5.3

Lifestyle intervention in PCOS

Thomas Reinehr (Dattlen, Germany)

09:09
HALL B
Session starts at 08:00

WG5.4

Androgen Excess in female athletes

Angelica Lindén Hirschberg (Stockholm, Sweden)

09:32
HALL B
Session starts at 08:00

WG5.5

Contraception in adolescence

Kathy Hoeger (Rochester, USA)

08:00 - 10:00

ESPE Working Group on Gender Dysphoria (GD)

HALL C

Gary Butler (London, United Kingdom)

08:00
HALL C
Session starts at 08:00

WG6.1

Assessing competence to consent to physical treatment in transgender adolescents

Annelou De Vries (Amsterdam, The Netherlands)

08:30
HALL C
Session starts at 08:00

WG6.2

Surgical options for the transfemale

Mark-Bram Bouman (Amsterdam, The Netherlands)

09:00
HALL C
Session starts at 08:00

WG6.3

Surgical options for the transmale

Nim Christopher (London, United Kingdom)

09:30
HALL C
Session starts at 08:00

WG6.4

Annual General Meeting

08:00 - 10:00

ESPE Working Group on Turner Syndrome (TS)

HALL A

Michael Ranke (Tuebingen, Germany), Aneta Gawlik (Katowice, Poland), Malcolm Donaldson (Glasgow, United Kingdom) & Christina Kanaka-Gantenbein (Athens, Greece)

08:00
HALL A
Session starts at 08:00

Introduction

08:05
HALL A
Session starts at 08:00

WG7.1

Oral versus transdermal induction of puberty - The Turner Working Group of ESPE proposal

Malcolm Donaldson (Glasgow, United Kingdom)

08:15
HALL A
Session starts at 08:00

WG7.2

Theoretical and practical implications of transdermal approach to pubertal induction

Berit Kristrom (Umeå, Sweden)

08:30
HALL A
Session starts at 08:00

Discussion

08:40
HALL A
Session starts at 08:00

WG7.3

Endocrine management of Turner Syndrome in adolescents and early adulthood

Melanie Davis (London, United Kingdom)

09:05
HALL A
Session starts at 08:00

WG7.4

Fertility preservation- technical and ethical aspects

Kathrin Fleischer (Nijmegen, The Netherlands)

09:30
HALL A
Session starts at 08:00

WG7.5

Cardiac morbidity and mortality during pregnancy in TS

Anthonie Duijnhouwers (Nijmegen, The Netherlands)

09:55
HALL A
Session starts at 08:00

Closing remarks

10:00 - 10:30

REFRESHMENT BREAK, POSTERS & EXHIBTION

Exhibition Area

10:30 - 10:45

OPENING CEREMONY

HALL A

10:45 - 11:15

PLENARY 1 - RANKL and RANK: Bone and Beyond

HALL A

Chairs: Gabriele Häusler (Vienna, Austria) & Agnès Linglart (Paris, France)

HALL A
Session starts at 10:45

PL1

RANKL and RANK: Bone and beyond

Josef Penninger (Vancouver, Canada)

11:15 - 11:45

ESPE AWARDS - Henning Andersen Prizes

HALL A

Mehul Dattani (London, United Kingdom)

12:00 - 13:30

SYMPOSIUM 1

Novel advances in Diabetes and Obesity

HALL B

Chairs: Martin Wabitsch (Ulm, Germany) & Jan Lebl (Prague, Czech Republic)

HALL B
Session starts at 12:00

S1.1

Off the weight curve – dynamics of childhood obesity

Antje Körner (Leipzig, Germany)

HALL B
Session starts at 12:00

S1.2

The gut microbiome and Obesity

Frank Scott (Denver, USA)

HALL B
Session starts at 12:00

S1.3

New developments for treatments in monogenic disorders focusing on setmelanotide trials

Christine Poitou (Paris, France)

12:00 - 13:30

SYMPOSIUM 2

What’s new in bone and growth plate research.

E1

Chairs: Wolfgang Högler (Linz, Austria) & Dov Tiosano (Haifa, Israel)

E1
Session starts at 12:00

S2.1

Longitudinal bone growth: fundamental mechanisms to clinical applications

Jeffrey Baron (Bethesda, USA)

E1
Session starts at 12:00

S2.2

Anabolic therapies for osteoporosis in childhood

Frank Rauch (Montreal, Canada)

E1
Session starts at 12:00

S2.3

Steroid-Associated Osteoporosis in the Pediatric Population

Leanne Ward (Ottawa, Canada)

12:00 - 13:30

SYMPOSIUM 3

Novel insights in our understanding of Disorders of Sex Development: From Genes to Clinical Outcomes

HALL A

Chairs: Olaf Hiort (Lubeck, Germany) & Laura Audi (Barcelona, Spain)

HALL A
Session starts at 12:00

S3.1

Genetics of DSD – do we understand it?

Anu Bashamboo (Paris, France)

HALL A
Session starts at 12:00

S3.2

Outcomes in DSD – insight from the DSD life study

Anna Nordenström (Stockholm, Sweden)

HALL A
Session starts at 12:00

S3.3

Novel insights into sex determination

Andy Greenfield (Oxford, United Kingdom)

12:00 - 13:30

SYMPOSIUM 4

ISPAD/ESPE Symposium - Complications of Type 1 Diabetes

HALL C

Chairs: Zdeněk Šumník (Prague, Czech Republic) & Thomas Danne (Hanover, Germany)

HALL C
Session starts at 12:00

S4.1

Hypoglycemia in children with T1D: Past, Present, and Future

David Maahs (Stanford, USA)

HALL C
Session starts at 12:00

S4.2

Novel advances in diabetic retinopathy screening and management

Kim Donaghue (Sydney, Australia)

HALL C
Session starts at 12:00

S4.3

Prediction of renal and cardiovascular complications

Loredana Marcovecchio (Cambridge, United Kingdom)

12:00 - 13:30

ESPE ACTIVITIES

E2

E2
Session starts at 12:00

ACT1

eLearning RLC portal

Annemieke Boot & Mona Karem (Groningen, The Netherlands & Ismailia, Egypt)

E2
Session starts at 12:00

ACT2

Science Committee activities

Faisal Ahmed & Agnes Linglart (Glasgow, United Kingdom & Le Kremlin-Bicetre, France)

E2
Session starts at 12:00

ACT3

Education and training activities

Rasa Verkauskiene, Malcolm Donaldson & Violeta Iotova (Kaunas, Lithuania, Glasgow, Scotland & Varna, Bulgaria)

13:30 - 14:45

LUNCH, POSTERS & EXHIBITION

Exhibition Area

13:45 - 14:45

Industry Sponsored Satellite Symposia

14:45 - 15:45

MEET THE EXPERT 1.1

Holistic approach to the individual with DSD

HALL B

HALL B
Session starts at 14:45

MTE1.1

Holistic approach to the individual with DSD

Martine Cools (Gent, Belgium)

14:45 - 15:45

MEET THE EXPERT 2.1

The interpretation of abnormal thyroid function tests in children and adolescents

HALL C

HALL C
Session starts at 14:45

MTE2.1

The interpretation of abnormal thyroid function tests in children and adolescents

Carla Moran (Cambridge, United Kingdom)

14:45 - 16:15

HOW DO I...

HOW DO I... SESSION 1

HALL A

Chair: John Gregory (Cardiff, United Kingdom)

14:45
HALL A
Session starts at 14:45

HDI1.1

How Do I... Manage subclinical hypothyroidism

Mariacarolina Salerno (Naples, Italy)

15:15
HALL A
Session starts at 14:45

HDI1.2

How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults?

Maithé Tauber (Toulouse, France)

15:45
HALL A
Session starts at 14:45

HDI1.3

How do I... Manage a child with insulin resistance

Francesco Chiarelli (Chieti, Italy)

14:45 - 16:15

FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1

E2

Chairs: Elisabeth Steichen-Gersdorf (Innsbruck, Austria) & Dirk Schnabel (Berlin, Germany)

14:45
E2
Session starts at 14:45

RFC2.1

Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

Wolfgang Högler (Linz, Austria)

14:50
E2
Session starts at 14:45

RFC2.2

Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia?

Julia André (Le Kremlin Bicêtre, France)

14:55
E2
Session starts at 14:45

RFC2.3

Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children

David D Martin (Tübingen, Germany)

15:00
E2
Session starts at 14:45

RFC2.4

Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy

Natascia di Lorgi (Genova, Italy)

15:05
E2
Session starts at 14:45

RFC2.5

Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood

Theo Sas (Rotterdam, The Netherlands)

15:10
E2
Session starts at 14:45

RFC2.6

Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria

Andreas Kyriakou (Glasgow, United Kingdom)

15:15
E2
Session starts at 14:45

FC2.1

Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH)

Agnès Linglart (Le Kremlin-Bicêtre, France)

15:25
E2
Session starts at 14:45

FC2.2

Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial

Annemieke Boot (Groningen, The Netherlands)

15:35
E2
Session starts at 14:45

FC2.3

Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia

Volha Zhukouskaya (Le Kremlin-Bicêtre, France)

15:45
E2
Session starts at 14:45

FC2.4

New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)

Adalbert Raimann (Vienna, Austria)

15:55
E2
Session starts at 14:45

FC2.5

Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people

Huda M Elsharkasi (Glasgow, United Kingdom)

16:05
E2
Session starts at 14:45

FC2.6

Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses

David D Martin (Tübingen, Germany)

14:45 - 16:15

FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders

F1

Chairs: Leena Patel (Manchester, United Kingdom) & Senthil Senniappan (LIverpool, UK)

14:45
F1
Session starts at 14:45

RFC3.1

European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC)

Salma Ali (Glasgow, United Kingdom)

14:50
F1
Session starts at 14:45

RFC3.2

Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases

Laura Atger-Lallier (Paris, France)

14:55
F1
Session starts at 14:45

RFC3.3

The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort

Maha Abdulhadi-Atwan (Hebron, Palestine)

15:00
F1
Session starts at 14:45

RFC3.4

Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease

Shuji Sai (Sapporo, Japan)

15:05
F1
Session starts at 14:45

RFC3.5

Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors

Patrizia Bruzzi (Modena, Italy)

15:10
F1
Session starts at 14:45

RFC3.6

Prevalence of endocrine complications in Duchenne muscular dystrophy

Primož Kotnik (Ljubljana, Slovenia)

15:15
F1
Session starts at 14:45

FC3.1

Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report

Maki Fukami (Tokyo, Japan)

15:25
F1
Session starts at 14:45

FC3.2

CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis

Francesca Cirillo (Reggio Emilia, Italy)

15:35
F1
Session starts at 14:45

FC3.3

Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR)

Maria Natalia Rojas Velazquez (Bern, Switzerland)

15:45
F1
Session starts at 14:45

FC3.4

Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome

Satoshi Watanabe (Nagasaki, Japan)

15:55
F1
Session starts at 14:45

FC3.5

Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011

Samantha Lai-Ka Lee (Melbourne, Australia)

16:05
F1
Session starts at 14:45

FC3.6

Severe infections contribute to increased risk of early death in patients with apeced

Joonatan Borchers (Helsinki, Finland)

14:45 - 16:15

FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1

E1

Chairs: Sabine Hofer (Innsbruck, Austria) & Reinhard Holl (Ulm, Germany)

14:45
E1
Session starts at 14:45

RFC1.1

Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes

Kikumi Ushijima (Tokyo, Japan)

14:50
E1
Session starts at 14:45

RFC1.2

Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism

Zhou Pei (Shanghai, China)

14:55
E1
Session starts at 14:45

RFC1.3

The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes

Jose Antonio Orozco Morales (Mexico City, Mexico)

15:00
E1
Session starts at 14:45

RFC1.4

Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS

Luis Salamanca (Madrid, Spain)

15:05
E1
Session starts at 14:45

RFC1.5

Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children

Caiqi Du (Wuhan, China)

15:10
E1
Session starts at 14:45

RFC1.6

An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus

Nancy Elbarbary (Cairo, Egypt)

15:15
E1
Session starts at 14:45

FC1.1

Insulin resistance leads to mitochondrial dysfunction in hepatocyte

Hong Chen (Hangzhou, China)

15:25
E1
Session starts at 14:45

FC1.2

Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells

Kyung-Mi Jang (Daegu, Republic of Korea)

15:35
E1
Session starts at 14:45

FC1.3

Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases

Amalia Sertedaki (Athens, Greece)

15:45
E1
Session starts at 14:45

FC1.4

ABSTRACT WITHDRAWN

15:55
E1
Session starts at 14:45

FC1.5

FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome

Georgina Williams (Chippenham, United Kingdom)

16:05
E1
Session starts at 14:45

FC1.6

A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children

Noah Gruber (Ramat Gan, Israel)

16:15 - 16:30

REFRESHMENT BREAK, POSTERS AND EXHIBITION

Exhibition Area

16:30 - 17:00

PLENARY 2

Light, Body Clocks and Sleep: Biology to New Therapeutics

HALL A

Peter Clayton (Manchester, United Kingdom) & Annette Grüters (Heidelberg, Germany)

HALL A
Session starts at 16:30

PL2

Light, Body Clocks and Sleep: Biology to New Therapeutics

Russell Foster (Oxford, United Kingdom)

17:00 - 18:00

MEET THE EXPERT 3.1

Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

HALL B

HALL B
Session starts at 17:00

MTE3.1

Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting

Claus Højbjerg Gravholt (Aarhus, Denmark)

17:00 - 18:00

MEET THE EXPERT 4.1

Klinefelter syndrome - when should testosterone be started

HALL C

HALL C
Session starts at 17:00

MTE4.1

Klinefelter syndrome - when should testosterone be started

Julia Rohayem (Münster, Germany)

17:00 - 18:00

YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1

HALL A

Wieland Kiess (Liepzig, Germany)

17:00
HALL A
Session starts at 17:00

YB1.1

Adrenals

Evangelia Charmandari (Athens, Greece)

17:12
HALL A
Session starts at 17:00

YB1.2

Antenatal and Neonatal Endocrinology

Khalid Hussain (Doha, Qatar)

17:24
HALL A
Session starts at 17:00

YB1.3

Bone, Growth Plate and Mineral Metabolism

Ola Nilsson (Stockholm, Sweden)

17:36
HALL A
Session starts at 17:00

YB1.4

Type 2 Diabetes, Metabolic Syndrome and Lipids

Orit Hamiel (Tel Aviv, Israel)

17:48
HALL A
Session starts at 17:00

YB1.5

Editor's Choice

Ken Ong (Cambridge, United Kingdom)

17:00 - 18:30

FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid

E2

Chairs: Malgorzata Wasniewska (Messina, Italy) & A. S. Paul Van-Trotsenburg (Amsterdam, The Netherlands)

17:00
E2
Session starts at 17:00

RFC5.1

Hurthle cell carcinoma in childhood retrospective analysis of a large series

Giorgia Pepe (Messina, Italy)

17:05
E2
Session starts at 17:00

RFC5.2

Ultrasound features of multinodular goiter in DICER1 syndrome

Marek Niedziela (Poznan, Poland)

17:10
E2
Session starts at 17:00

RFC5.3

Experience of thyroid surgery in children with intraoperative neuromonitoring

Alexander Anikiev (Moscow, Russian Federation)

17:15
E2
Session starts at 17:00

RFC5.4

Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience

Sommayya Aftab (London, United Kingdom)

17:20
E2
Session starts at 17:00

RFC5.5

A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant

Eve Stern (Ramat Gan, Israel)

17:25
E2
Session starts at 17:00

RFC5.6

Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency

Fang Yanlan (Hangzhou, China)

17:30
E2
Session starts at 17:00

FC5.1

Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis

Claire Wood (Newcastle upon Tyne, United Kingdom)

17:40
E2
Session starts at 17:00

FC5.2

Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases

Karolina Stożek (Bialystok, Poland)

17:50
E2
Session starts at 17:00

FC5.3

Predominant DICER1 mutations in pediatric follicular thyroid carcinomas

Young Ah Lee (Seoul, Republic of Korea)

18:00
E2
Session starts at 17:00

FC5.4

Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer

Stéphanie Larrivée-Vanier (Montreal, Canada)

18:10
E2
Session starts at 17:00

FC5.5

Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis

Daniela Choukair (Heidelberg, Germany)

18:20
E2
Session starts at 17:00

FC5.6

Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism

Atsushi Suzuki (Nagoya, Japan)

17:00 - 18:30

FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity

E1

Chairs: Julie Chowen (Madrid, Spain) & Moshe Philip (Petah Tikva, Israel)

17:00
E1
Session starts at 17:00

RFC4.1

Expression of miRNAs in circulating exosomes derived from patients with NAFLD

Junfen Fu (Zhejiang, China)

17:05
E1
Session starts at 17:00

RFC4.2

Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid

Xuelian Zhou (Hangzhou, China)

17:10
E1
Session starts at 17:00

RFC4.3

Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters

Judit Bassols (Salt, Spain)

17:15
E1
Session starts at 17:00

RFC4.4

The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells

Anna Kirstein (Leipzig, Germany)

17:20
E1
Session starts at 17:00

RFC4.5

GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice

Feihong Luo (Shanghai, China)

17:25
E1
Session starts at 17:00

RFC4.6

Appetite suppressing effects of glucoregulatory peptides devoid of nausea

Christian L Roth (Seattle, USA)

17:30
E1
Session starts at 17:00

FC4.1

Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins

Mitra Nourbakhsh (Tehran, Islamic Republic of Iran)

17:40
E1
Session starts at 17:00

FC4.2

Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children

Martha Hanschkow (Leipzig, Germany)

17:50
E1
Session starts at 17:00

FC4.3

Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size

Marta Díaz (Barcelona, Spain)

18:00
E1
Session starts at 17:00

FC4.4

The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children

Anna Di Sessa (Naples, Italy)

18:10
E1
Session starts at 17:00

FC4.5

Leptin gene methylation status in Egyptian infants

Omneya Magdy Omar (Alexandria, Egypt)

18:30
E1
Session starts at 17:00

FC4.6

Brain satiety responses to a meal in children before and after weight management intervention

Christian L Roth (Seattle, USA)

18:30 - 20:00

Industry-Sponsored Satellite Symposia

20:00 - 21:30

Informal ESPE Networking Event

ESPE - European Society of Paediatric Endocrinology

In this section

© ESPE 2017